AAPGNGMHealthcare·Biotechnology#91 in industry

Ascentage Pharma Group Internat

-8.7% · 90d

$23.37

-0.58 (-2.42%)

After-Hours $23.35(+0.05)

News

(1)

April 2026

Apr 20, 20261 week ago6-KHealthcare

AAPG Presents Synergy Data on Combination Drugs Against Resistant Cancers

AAPGASCENTAGE PHARMA GROUP INTERNATIONAL

# 📰 What This Document Is This document is a filing (6-K) and a voluntary announcement detailing scientific research presented by Ascentage Pharma Group International (AAPG). Essentially, the company is sharing its latest, most promising preclinical findings from a poster presentation at the Americ

Read summaryView on SEC EDGAR

Key Data

Market Cap$2.18B

Open$23.50

Prev Close$23.95

Day Range$23.24 – $23.50

52W Range$19.11 – $48.45

Volume1,685

P/E (TTM)—

EPS$-2.05

Dividend Yield—

Beta0.81

Profit Margin-216.47%

Revenue Growth117.00%

Price Target$49.00(+109.7%)

Next Earnings2026-03-25

Analyst Ratings

Strong Buy7 analysts

Buy 7Hold 0Sell 0

About

Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company's primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation. It also develops APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interactions to treat solid tumors and hematological malignancies; and APG-1252, a small molecule drug to restore apoptosis through dual inhibition of the Bcl-2 and Bcl-xL proteins for the treatment of small-cell lung cancer, non-small cell lung cancer, neuroendocrine tumor, and non-Hodgkin's lymphoma. In addition, the company is developing APG-1387, a small-molecule inhibitor of apoptosis proteins for advanced solid tumors and chronic HBV infection; APG-2449, an oral inhibitor of FAK, ROS1, and ALK kinases; APG-5918, an orally available and selective embryonic ectoderm development inhibitor. In addition, it is involved in medical research and development; clinical development; clinical trials operations; venture capital investment; rental of buildings; and provision of science and technology promotion services. The company has collaboration relationships with biotechnology and pharmaceutical companies; and research institutions. Ascentage Pharma Group International was founded in 2009 and is headquartered in Suzhou, China.

Healthcare · Biotechnology

767 employees

www.ascentage.cn